Chae Young Lim is the CTO at Huonslab Co., Ltd., S. Korea.
He is an accomplished R&D executive with more than 28 years of experience in the development of recombinant protein therapeutics including peptides, antibodies and Biosimilars/Stand alone.

Prior to Huonslab, he served as Vice President of R&D Center at Humedix, a subsidiary of Huons Global for 12 years and received Jang Yeong-Sil Award for his extraordinary technology development work for Elavier Premier Hyaluronic acid Filler, and also IR52 Jang Yeong-Sil Award for his innovative approaches in the management of R&D organization in 2014.

He brings an impressive proven track record to Huonslab in the research and development of hyaluronan acid based HA derma-fillers (Elavier Premier) and also HA injections such as Humia Inj. for the treatment of knee osteoarthritis at Humedix.

Before Humedix, he was Head of Division, R&D center at HLB Pharmaceuticals, responsible for the development of antiplatelet peptide drug, Bivarirudin and Principle Scientist at Dong Kook Pharmaceuticals.

He holds a M.Sc. in Biological Engineering from Konkuk University and KIST (Korea Institute of Science & Technology).